WO1999015553A3 - Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung - Google Patents

Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung Download PDF

Info

Publication number
WO1999015553A3
WO1999015553A3 PCT/DE1998/002896 DE9802896W WO9915553A3 WO 1999015553 A3 WO1999015553 A3 WO 1999015553A3 DE 9802896 W DE9802896 W DE 9802896W WO 9915553 A3 WO9915553 A3 WO 9915553A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
molecule
polypeptide
costimulating
involve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1998/002896
Other languages
English (en)
French (fr)
Other versions
WO1999015553A2 (de
Inventor
Richard Kroczek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Robert Koch Institute
Original Assignee
Robert Koch Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26040229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1999015553(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19821060A external-priority patent/DE19821060A1/de
Application filed by Robert Koch Institute filed Critical Robert Koch Institute
Priority to US09/509,283 priority Critical patent/US7259247B1/en
Priority to AU13320/99A priority patent/AU752433B2/en
Priority to DE59813875T priority patent/DE59813875D1/de
Priority to JP2000512857A priority patent/JP4463418B2/ja
Priority to CA2305350A priority patent/CA2305350C/en
Priority to EP98956800A priority patent/EP1017723B1/de
Publication of WO1999015553A2 publication Critical patent/WO1999015553A2/de
Publication of WO1999015553A3 publication Critical patent/WO1999015553A3/de
Anticipated expiration legal-status Critical
Priority to US09/823,307 priority patent/US7132099B2/en
Priority to US09/972,524 priority patent/US7125551B2/en
Priority to AU2002323894A priority patent/AU2002323894B2/en
Priority to US10/647,072 priority patent/US7306800B2/en
Priority to US11/977,342 priority patent/US20090074784A1/en
Priority to US11/977,334 priority patent/US7722872B2/en
Priority to US11/977,335 priority patent/US20080118513A1/en
Priority to US12/732,360 priority patent/US20120045447A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Die Erfindung betrifft ein Polypeptid (8F4-Molekül) mit der biologischen Aktivität der Ko-Stimulation von T-Zellen. Weiterhin betrifft die Erfindung monoklonale Antikörper gegen das 8F4-Molekül und Hybridomzellen, die die monoklonalen Antikörper herstellen. Ferner betrifft die Erfindung die Verwendung von Substanzen, die die biologische Aktivität des erfindungsgemäßen Polypeptids 8F4 hemmen, insbesondere monoklonale Antikörper, natürliche oder synthetische Liganden, Agonisten oder Antagonisten, als Arzneimittel, insbesondere zur Vorbeugung oder Therapie von Erkankungen, an denen das Immunsystem beteiligt ist. Ferner betrifft die Erfindung die Verwendung des 8F4-Moleküls oder von Zellen, die das 8F4-Molekül enthalten, als Arzneimittel, insbesondere zur Vorbeugung oder Therapie von Erkrankungen, an denen das Immunsystem beteiligt ist. Weiterhin betrifft die Erfindung die Verwendung von Substanzen, die das erfindungsgemäße Polypeptid spezifisch erkennen, insbesondere monoklonale Antikörper, natürliche oder synthetische Liganden, Agonisten oder Antagonisten, zur Diagnose von Erkrankungen, an denen das Immunsystem beteiligt ist.
PCT/DE1998/002896 1997-09-23 1998-09-23 Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung Ceased WO1999015553A2 (de)

Priority Applications (14)

Application Number Priority Date Filing Date Title
US09/509,283 US7259247B1 (en) 1997-09-23 1998-09-23 Anti-human T-cell costimulating polypeptide monoclonal antibodies
AU13320/99A AU752433B2 (en) 1997-09-23 1998-09-23 Costimulating T-cell polypeptide, monoclonal antibodies, their preparation and use
DE59813875T DE59813875D1 (de) 1997-09-23 1998-09-23 Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
JP2000512857A JP4463418B2 (ja) 1997-09-23 1998-09-23 Ｔ細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用
CA2305350A CA2305350C (en) 1997-09-23 1998-09-23 Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof
EP98956800A EP1017723B1 (de) 1997-09-23 1998-09-23 Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
US09/823,307 US7132099B2 (en) 1997-09-23 2001-04-02 Methods of modulating T lymphocyte costimulation with an antibody to an 8F4 polypeptide
US09/972,524 US7125551B2 (en) 1997-09-23 2001-10-04 Methods for treatment of asthmatic disorders using a monoclonal antibody to 8F4 polypeptide
AU2002323894A AU2002323894B2 (en) 1997-09-23 2002-12-19 Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
US10/647,072 US7306800B2 (en) 1997-09-23 2003-08-22 Treatment of autoimmune disorders with antibodies to costimulating polypeptide of T cells
US11/977,342 US20090074784A1 (en) 1997-09-23 2007-10-23 Treatment of chronic viral diseases with antibodies to costimulating polypeptide of T cells
US11/977,334 US7722872B2 (en) 1997-09-23 2007-10-23 Treatment of cancer with antibodies to costimulating polypeptide of T cells
US11/977,335 US20080118513A1 (en) 1997-09-23 2007-10-23 Treatment of immune disorders with antibodies to costimulating polypeptide of T cells
US12/732,360 US20120045447A1 (en) 1997-09-23 2010-03-26 T cell costimulating polypeptides and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19741929.1 1997-09-23
DE19741929 1997-09-23
DE19821060.4 1998-05-11
DE19821060A DE19821060A1 (de) 1997-09-23 1998-05-11 Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US09/509,283 A-371-Of-International US7259247B1 (en) 1997-09-23 1998-09-23 Anti-human T-cell costimulating polypeptide monoclonal antibodies
US09/823,307 Continuation US7132099B2 (en) 1997-09-23 2001-04-02 Methods of modulating T lymphocyte costimulation with an antibody to an 8F4 polypeptide
US09/972,524 Continuation US7125551B2 (en) 1997-09-23 2001-10-04 Methods for treatment of asthmatic disorders using a monoclonal antibody to 8F4 polypeptide
US10/647,072 Continuation US7306800B2 (en) 1997-09-23 2003-08-22 Treatment of autoimmune disorders with antibodies to costimulating polypeptide of T cells

Publications (2)

Publication Number Publication Date
WO1999015553A2 WO1999015553A2 (de) 1999-04-01
WO1999015553A3 true WO1999015553A3 (de) 1999-05-20

Family

ID=26040229

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1998/002896 Ceased WO1999015553A2 (de) 1997-09-23 1998-09-23 Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung

Country Status (8)

Country Link
US (2) US7259247B1 (de)
EP (1) EP1017723B1 (de)
JP (1) JP4463418B2 (de)
AU (1) AU752433B2 (de)
CA (1) CA2305350C (de)
DE (1) DE59813875D1 (de)
ES (1) ES2279585T3 (de)
WO (1) WO1999015553A2 (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8309083B2 (en) 1999-02-03 2012-11-13 Amgen, Inc. Polypeptides involved in immune response
US8470317B2 (en) 1999-02-03 2013-06-25 Amgen Inc. B7RP-1 antagonists
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
CA2305350C (en) 1997-09-23 2015-04-07 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
CA2346496A1 (en) * 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
WO2001012658A2 (en) * 1999-08-11 2001-02-22 Isis Innovations Limited Human icos ligand and application thereof
JP3871503B2 (ja) * 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
EP1900816A3 (de) * 1999-09-21 2008-03-26 Genetics Institute, LLC GL50-Moleküle und Verwendungen davon
PT1218504E (pt) * 1999-09-21 2007-10-22 Genetics Inst Llc Novas moléculas gl50 e suas utilizações
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
EP2042596B1 (de) * 2000-11-28 2015-02-11 Amgen Inc. Neue Polypeptide, die an der Immunabwehr beteiligt sind
WO2002074803A2 (en) * 2001-01-16 2002-09-26 Bayer Aktiengesellschaft Regulation of human icos v protein
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
ES2442386T3 (es) 2004-04-23 2014-02-11 Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
AU2011304728A1 (en) 2010-09-20 2013-03-14 Biontech Ag Antigen-specific T cell receptors and T cell epitopes
MX373443B (es) * 2011-03-31 2020-05-20 Inst Nat Sante Rech Med Anticuerpos dirigidos contra icos y usos de los mismos.
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US10280221B2 (en) 2013-03-15 2019-05-07 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
RS60614B1 (sr) 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos
MX2018002610A (es) 2015-09-02 2018-09-27 Immutep Sas Anticuerpos anti-lag-3.
CA2998208A1 (en) 2015-10-22 2017-04-27 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
CA3032897A1 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
EP3728314A1 (de) 2017-12-19 2020-10-28 Kymab Limited Bispezifischer antikörper für icos und pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
CN114174537A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
RS66646B1 (sr) 2019-10-28 2025-04-30 Medimmune Ltd Formulacije suvog praška vezujućih antitela za timusni stromalni limfopoetin (tslp) i postupci njihove upotrebe
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
CA3190660A1 (en) 2020-08-31 2022-03-03 George C. Lee Cell localization signature and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
SMT202500208T1 (it) 2020-12-28 2025-07-22 Bristol Myers Squibb Co Composizioni anticorpali e metodi per il loro uso
EP4314068A1 (de) 2021-04-02 2024-02-07 The Regents Of The University Of California Antikörper gegen gespaltenes cdcp1 und verwendungen davon
TW202313682A (zh) 2021-05-18 2023-04-01 英商凱麥博有限公司 抗icos抗體之用途
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
JP2025509749A (ja) 2022-03-18 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー ポリペプチドの単離方法
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies
CN119562830A (zh) 2022-06-02 2025-03-04 百时美施贵宝公司 抗体组合物及其使用方法
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989010398A1 (en) * 1988-04-26 1989-11-02 Ellco Food Ab Blood platelet lysate, method of its preparation and a cell culture medium containing said blood platelet lysate
WO1990004180A1 (en) * 1988-10-06 1990-04-19 T Cell Sciences, Inc. Therapeutic and diagnostic methods using soluble t cell surface molecules
WO1998038216A1 (en) * 1997-02-27 1998-09-03 Japan Tobacco Inc. Cell surface molecule mediating cell adhesion and signal transmission

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
CA2305350C (en) 1997-09-23 2015-04-07 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989010398A1 (en) * 1988-04-26 1989-11-02 Ellco Food Ab Blood platelet lysate, method of its preparation and a cell culture medium containing said blood platelet lysate
WO1990004180A1 (en) * 1988-10-06 1990-04-19 T Cell Sciences, Inc. Therapeutic and diagnostic methods using soluble t cell surface molecules
WO1998038216A1 (en) * 1997-02-27 1998-09-03 Japan Tobacco Inc. Cell surface molecule mediating cell adhesion and signal transmission

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FREEMAN G J ET AL: "CLONING OF B-2: A CTLA-4 COUNTER-RECEPTOR THAT COSTIMULATES HUMAN T CELL PROLIFERATION", SCIENCE, vol. 262, 5 November 1993 (1993-11-05), pages 909 - 911, XP002069402 *
LANIER L L ET AL: "CD80 (B7) AND CD86 (B70) PROVIDE SIMILAR COSTIMULATORY SIGNALS FOR T CELL PROLIFERATION, CYTOKINE PRODUCTION, AND GENERATION OF CTL", JOURNAL OF IMMUNOLOGY, vol. 154, 1 January 1995 (1995-01-01), pages 97 - 105, XP002018932 *
TAMATANI T, TEZUKA K: "Human cell surface protein encoding cDNA", GENESEQ DATABASE, ACCESSION NUMBER V53199, XP002094462 *
TAMATANI T, TEZUKA K: "Human Cell Surface Protein", GENESEQ DATABASE, ACCESSION NUMBER W75956, XP002094461 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8309083B2 (en) 1999-02-03 2012-11-13 Amgen, Inc. Polypeptides involved in immune response
US8470317B2 (en) 1999-02-03 2013-06-25 Amgen Inc. B7RP-1 antagonists
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Also Published As

Publication number Publication date
CA2305350A1 (en) 1999-04-01
JP2001517425A (ja) 2001-10-09
CA2305350C (en) 2015-04-07
US7259247B1 (en) 2007-08-21
DE59813875D1 (de) 2007-02-22
EP1017723B1 (de) 2007-01-10
ES2279585T3 (es) 2007-08-16
AU1332099A (en) 1999-04-12
US20080118513A1 (en) 2008-05-22
WO1999015553A2 (de) 1999-04-01
AU752433B2 (en) 2002-09-19
JP4463418B2 (ja) 2010-05-19
EP1017723A2 (de) 2000-07-12

Similar Documents

Publication Publication Date Title
WO1998018826A3 (en) Anti-CCR5 antibodies and methods of use therefor
IL140138A0 (en) Specific antibodies of tie-2 ligands
CA2182289A1 (en) Immuno-stimulatory monoclonal antibodies
AU1332099A (en) Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
EP0821728A4 (de) Tie-2 liganden, herstellungsverfahren und verwendung
ZA891861B (en) Monoclonal antibodies
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
Newman Selective blockade of human natural killer cells by a monoclonal antibody.
NO985904L (no) TIE-2-reseptorligander (TIE-ligand-3, TIE-ligand-4), samt anvendelse derav
Neumaier et al. Delineation of four carcinoembryonic antigen (CEA) related antigens in normal plasma by transblot studies using monoclonal anti-CEA antibodies with different epitope specificities
Koyasu et al. Signals for activation and proliferation of murine T lymphocyte clones.
FI885797A7 (fi) Peptidejä, menetelmä niiden valmistamiseksi, niiden käyttö vasta-aineiden valmistamiseksi, sekä näiden käyttö ihmisen veren PAI-1-aktiivisuuden estämiseksi
AU2347501A (en) Trp-protein-related mtr1 protein and dna sequence coding therefor
Baryshnikov et al. ICO-1 monoclonal antibodies against the constant region of Ia-like (Dr) antigens
ZA9710391B (en) Method of preparing a monoclonal antibody, monoclonal antibody, a pharmaceutical composition and a diagnostic reagent.
Svep et al. C1q PRECIPITIN IN THE SERA OF PATIENTS WITH ALLERGIC VASCULITIS (GOUGEROT-RUITER SYNDROME)
Boyle et al. Nerve growth factor can initiate the classical complement pathway by specif substitution for C1̄
Borsos et al. Lack of C4 binding by human igM during activation of the classical pathway
Brown et al. Biological effects of anti-pneumococcal (Pn) antibody and complement in Pn bacteremia
Lawrence et al. Kappa Opioid Receptors on Three Related Thymoma Cell Lines are Coupled to Adenylyl Cyclase With Different Efficiency
Baryshnikov et al. Monoclonal antibodies against the alpha-chain of human lymphocyte function-associated antigen-1
WO1994026924A3 (en) MONOCLONAL ANTIBODIES AGAINST THE α-TNF TYPE I RECEPTOR, PROCESS FOR THE PRODUCTION AND USE THEREOF
EP0221365A3 (de) Monoklonaler Antikörper, der mit Legionella pneumophila reagiert

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2305350

Country of ref document: CA

Ref country code: CA

Ref document number: 2305350

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 13320/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998956800

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998956800

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09509283

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 13320/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998956800

Country of ref document: EP